GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (TSX:SVA) » Definitions » EV-to-FCF

Sernova Biotherapeutics (TSX:SVA) EV-to-FCF : -2.58 (As of Apr. 01, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sernova Biotherapeutics's Enterprise Value is C$50.25 Mil. Sernova Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2025 was C$-19.48 Mil. Therefore, Sernova Biotherapeutics's EV-to-FCF for today is -2.58.

The historical rank and industry rank for Sernova Biotherapeutics's EV-to-FCF or its related term are showing as below:

TSX:SVA' s EV-to-FCF Range Over the Past 10 Years
Min: -2.5   Med: 0   Max: 0
Current: -2.5

TSX:SVA's EV-to-FCF is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 3.34 vs TSX:SVA: -2.50

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-01), Sernova Biotherapeutics's stock price is C$0.155. Sernova Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was C$-0.080. Therefore, Sernova Biotherapeutics's PE Ratio (TTM) for today is At Loss.


Sernova Biotherapeutics EV-to-FCF Historical Data

The historical data trend for Sernova Biotherapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics EV-to-FCF Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.50 -43.57 -13.10 -6.93 -4.02

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.05 -4.38 -2.95 -4.02 -3.68

Competitive Comparison of Sernova Biotherapeutics's EV-to-FCF

For the Biotechnology subindustry, Sernova Biotherapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's EV-to-FCF falls into.


;
;

Sernova Biotherapeutics EV-to-FCF Calculation

Sernova Biotherapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=50.254/-19.475
=-2.58

Sernova Biotherapeutics's current Enterprise Value is C$50.25 Mil.
Sernova Biotherapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-19.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sernova Biotherapeutics  (TSX:SVA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sernova Biotherapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.155/-0.080
=At Loss

Sernova Biotherapeutics's share price for today is C$0.155.
Sernova Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.080.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sernova Biotherapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.
Executives
Steven Sangha Director
Brett Alexander Whalen Director
Jeffrey Bacha Director

Sernova Biotherapeutics Headlines

From GuruFocus

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022

SINOVAC to Showcase Products at CPHI Frankfurt

By Business Wire Business Wire 10-28-2022